JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA

SYLVIA LUKE
LT GOVERNOR
KE KE'ENA

JORDAN LOWE
DIRECTOR

MICHAEL VINCENT
Deputy Director
Administration

JARED K. REDULLA
Deputy Director
Law Enforcement

STATE OF HAWAI'I | KA MOKU'ĀINA O HAWAI'I
DEPARTMENT OF LAW ENFORCEMENT
Ka 'Oihana Ho'okō Kānāwai
715 South King Street
Honolulu, Hawai'i 96813

No. **2025-0011**

January 13, 2025

The Honorable Ronald D. Kouchi
President and Members of the Senate
Thirty-Third Legislature
State Capitol, Room 409

The Honorable Nadine K. Nakamura
Speaker and Members of the House of
Thirty-Third Legislature
State Capitol, Room 431

Dear President Kouchi, Speaker Nakamura, and Members of the Legislature:

For your information and consideration, I am transmitting a copy of the Department of Law Enforcement (DLE)'s Annual Report on New Controlled Substances to the 2025 Legislature. In accordance with Section 93-16, Hawaii Revised Statutes, this report will be posted on DLE's website for ease of public viewing on the internet.

Sincerely,

Jordan Lowe
Director

DEPARTMENT OF LAW ENFORCEMENT
REPORT TO THE 2025 LEGISLATURE

NARCOTICS ENFORCEMENT DIVISION

NARCOTICS ENFORCEMENT DIVISION
ANNUAL REPORT TO THE 2025 LEGISLATURE
SECTION 329-11, HRS, REPORTING REQUIREMENTS

NOTICE OF FEDERAL SCHEDULING ACTIONS

Chapter 329-11(d) of the Hawaii Revised Statutes ("HRS") states that if a substance is added, deleted or rescheduled under federal law and notice of the designation is given to the Department of Law Enforcement, then the Department of Law Enforcement shall recommend to the legislature that a corresponding change in Hawaii law be made. The Department of Law Enforcement shall similarly designate the substance as added, deleted, or rescheduled under this chapter, after the expiration of thirty days from publication in the Federal Register of a final order, and this change shall have the effect of law. If a substance is added, deleted, or rescheduled under this subsection, the control shall be temporary and, if the next regular session of the state legislature has not made the corresponding changes in this chapter, the temporary designation of the added, deleted, or rescheduled substance shall be nullified.

During 2024, the Department of Law Enforcement was given notices via several different publications in the Federal Register of a final order, or interim final order, that the following substances, were either: 1) placed into the federal controlled substances schedules, or 2) removed from the controlled substances schedules by the United States Drug Enforcement Administration ("DEA"). Consequently, the Department issued and posted orders effecting the temporary changes required by statute at the Office of the Lieutenant Governor, Both the Senate and House Sergeant at Arms Offices at the State Capitol Building, and on the Department's website. Those orders add several controlled substances to the lists contained with section of chapter 329, HRS.

Additionally, several of the controlled substances listed in this report were not passed into law after required notices were made and a measure was introduced in the 2024 Legislature. As such, the DLE has added that previous list of controlled substances to its recommendation here for a legislative proposal in the 2025 Legislature.

The 2024 changes are as follows:

SCHEDULE I

1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one (commonly known as 2-methyl AP-237) , including its optical and geometric isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.

2-Methyl AP-237 has a pharmacological profile similar to other classical opioids such as fentanyl (schedule II), morphine (schedule II) and heroin (schedule I), which act as mu-opioid receptor agonists. Because of the pharmacological similarities of 2-methyl AP-237 to the aforementioned opioids, 2-methyl AP-237 presents a high risk of abuse and has negatively affected users and communities. According to the DEA Toxicology Testing Program (DEA TOX) [1] and a recent publication,[2] the abuse of 2-methyl AP-237 has been associated with at least seven fatalities in the United States between February 2020 and July 2023. The identification of this substance in post-mortem cases is a serious concern to public safety.

(59) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one)

Source: FR Doc. 2024-05543 03-15-24

2-(2-(4-ethoxybenzyl)-1 *H* -benzimidazol-1-yl)- *N,N* -diethylethan-1-amine (other names: Etodesnitazene; Etazene), 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1 *H* -benzimidazole (other names: *N* -pyrrolidino etonitazene; Etonitazepyne), and *N,N* -diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 *H* -benzimidazol-1-yl)ethan-1-amine (other name: Protonitazene), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts are possible within the specific chemical designation, in schedule I of the Controlled Substances Act.

Law enforcement reports demonstrate that etodesnitazene, *N* -pyrrolidino etonitazene, and protonitazene are being illicitly distributed and abused. The illicit use and distribution of these substances are similar to that of isotonitazene (schedule I) and prescription opioid analgesics. According to the National Forensic Laboratory Information System (NFLIS-Drug) database, which collects drug identification results from drug cases submitted to and analyzed by Federal, State and local forensic laboratories, there has been 596 reports for etodesnitazene, *N* -pyrrolidino

etonitazene, and protonitazene between January 2020 and May 2023 [5] (query date: May 15, 2023).

Etodesnitazene, *N* -pyrrolidino etonitazene, and Protonitazene have no currently accepted medical use in treatment in the United States, the Administrator has determined that Etodesnitazene, *N* -pyrrolidino etonitazene, and Protonitazene, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts are possible within the specific chemical designation, should be placed permanently in schedule I of the CSA.

(40) 2-(2-(4-ethoxybenzyl)-1 *H* -benzimidazol-1-yl)- *N,N* -diethylethan-1-amine (Other names: etodesnitazene; etazene)

(70) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1 *H* -benzimidazole (Other names: *N* -pyrrolidino etonitazene; etonitazepyne)

(97) *N,N* -diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 *H* -benzimidazol-1-yl)ethan-1-amine (Other name: protonitazene)

Source: FR Doc. 2024-07684 4-11-24

SCHEDULE IV

Zuranolone (chemically known as 1-[2-[(3 *R,* 5 *R,* 8 *R,* 9 *R,* 10 *S,* 13 *S,* 14 *S,* 17 *S*)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1 *H* -cyclopenta[*a*]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile)

Zuranolone (chemically known as 1-[2-[(3 *R,* 5 *R,* 8 *R,* 9 *R,* 10 *S,* 13 *S,* 14 *S,* 17 *S*)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1 *H* -cyclopenta[*a*]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile) is a new molecular entity with CNS activity. Zuranolone is a positive allosteric modulator of gamma-aminobutyric acid type A (GABAA) receptors and an inhibitory neurosteroid substance that shares structural features and a pharmacological mechanism of action with progesterone, alfaxalone (schedule IV), and brexanolone (allopregnanolone, schedule IV). Zuranolone shares a similar pharmacology profile with brexanolone (schedule IV) and benzodiazepines (schedule IV).

Source: FR Doc. 2023-23982 08-14-24

EMERGENCY CONTROLLED SUBSTANCE SCHEDULING ACTION

Section 329-11(e) of the Hawaii Revised Statutes authorizes the Administrator of the Department of Law Enforcement, Narcotics Enforcement Division (NED), to make an emergency scheduling by placing a substance into schedules I, II, action is necessary to avoid an imminent hazard or the possibility of an imminent hazard to the health and safety of the public. The Department shall post a public notice thirty days prior to the effective date of the emergency scheduling action, at the State Capitol, in the Office of the Lieutenant Governor, and on the Department's website for public inspection. If a substance is added or rescheduled under this subsection, the control shall be temporary and, if the next regular session of the State Legislature has not enacted the corresponding changes in this chapter, the temporary designation of the added or rescheduled substance shall be nullified.

In 2024, the Narcotics Enforcement Administrator did not order any emergency scheduling actions.

RECOMMENDED CHANGES TO STATUTE:

In accordance with sections 329-11 (d) of the HRS, the Department of Law Enforcement is recommending the following changes to state law in order to avoid the nullification of the temporary changes that have been made:

SECTION 1. Section 329-14, Hawaii Revised Statutes, is amended by amending subsection (b) to read as follows:

"(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

(2) Acetylmethadol;

(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers;

(4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl);

(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);

(6) Allylprodine;

(7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);

(8) Alphameprodine;

(9) Alphamethadol;

(10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);

(11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

(12) Alpha' -methyl butyryl fentanyl (2-methyl- N -(1-phenethylpiperidin-4-yl)- N -phenylbutanamide);

[~~(12)~~] (13) Benzethidine;

[~~(13)~~] (14) Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and salts of isomers;

[~~(14)~~] (15) Betacetylmethadol;

[~~(15)~~] (16) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

[~~(16)~~] (17) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);

[~~(17)~~] (18) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);

[~~(18)~~] (19) Betameprodine;

[~~(19)~~] (20) Betamethadol;

[~~(20)~~] (21) Beta-methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl);

[~~(21)~~] (22) Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl fentanyl);

[~~(22)~~] (23) Betaprodine;

(24) Brorphine 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2 *H* -benzo[*d*]imidazol-2-one;

[~~(23~~] (25) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);

[~~(24)~~] (26) Clonitazene;

[~~(25)~~] (27) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

[~~(26)~~] (28) Dextromoramide;

[~~(27)~~] (29) Diampromide;

[~~(28)~~] (30) Diethylthiambutene;

[~~(29)~~] (31) Difenoxin;

[~~(30)~~] (32) Dimenoxadol;

[~~(31)~~] (33) Dimepheptanol;

(34) 2′,5′-dimethoxyfentanyl (*N* -(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)- *N* -phenylpropionamide);

[~~(32)~~] (35) Dimethylthiambutene;

[~~(33)~~] (36) Dioxaphetyl butyrate;

[~~(34)~~] (37) Dipipanone;

[~~(35)~~] (38) 2-(2-(4-ethoxybenzyl)-1 H -benzimidazol-1-yl)- N,N -diethylethan-1-amine (other names: Etodesnitazene; Etazene);

(39) 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1 H -benzimidazole (other names: N -pyrrolidino etonitazene; Etonitazepyne);

(40) Ethylmethylthiambutene;

[~~(36)~~] (41) Etonitazene;

[~~(37)~~] (42) Etoxeridine;

[~~(38)~~] (43) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate);

[~~(39)~~] (44) 4-fluoroisobutyryl fentanyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other name: para-fluoroisobutyryl fentanyl);

[~~(40)~~] (45) 2'-fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other name: 2'-fluoro 2-fluorofentanyl);

[~~(41)~~] (46) Furanyl fentanyl (N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide);

[~~(45)~~] (47) 3-furanyl fentanyl (*N* -(1-phenethylpiperidin-4-yl)- *N* -phenylfuran-3-carboxamide);

[~~(42)~~] (48) Furethidine;

[~~(43)~~] (49) Hydroxypethidine;

(50) Isovaleryl fentanyl (3-methyl- *N* -(1-phenethylpiperidin-4-yl)- *N* -phenylbutanamide);

[~~(44)~~] (51) Ketobemidone;

[~~(45)~~] (52) Levomoramide;

[~~(46)~~] (53) Levophenacylmorphan;

(54) *Meta* -fluorofentanyl (*N* -(3-fluorophenyl)- *N* -(1-phenethylpiperidin-4-yl)propionamide);

(55) *Meta* -fluoroisobutyryl fentanyl (*N* -(3-fluorophenyl)- *N* -(1-phenethylpiperidin-4-yl)isobutyramide);

[~~(47)~~] (56) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

(57) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);

(58) Metonitazene *N,N* -diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1 *H* -benzimidazol-1-yl)ethan-1-amine;

[~~(48)~~] (59) 4'-methyl acetyl fentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);

[~~(49)~~] (60) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);

[~~(50)~~] (61) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

[~~(51)~~] (62) Morpheridine;

[~~(52)~~] (63) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

[~~(53)~~] (64) N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine (other name: Protonitazene);

(65) Noracymethadol;

[~~(54)~~] (66) Norlevorphanol;

[~~(55)~~] (67) Normethadone;

[~~(56)~~] (68) Norpipanone;

[~~(57)~~] (69) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide];

[~~(58)~~] (70) Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);

[~~(59)~~] (71) Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl);

(72) *Ortho* -fluorofuranyl fentanyl (*N* -(2-fluorophenyl)- *N* -(1-phenethylpiperidin-4-yl)furan-2-carboxamide);

[~~(60)~~] (73) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl);

[~~(61)~~] (74) Ortho-fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

[~~(62)~~] (75) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl);

[~~(63)~~] (76) Ortho-methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl methoxyacetyl fentanyl);

[~~(64)~~] (77) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

[~~(65)~~] (78) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide;

[~~(66)~~] (79) Para-fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);

(80) Para -methylcyclopropyl fentanyl (N -(4-methylphenyl)- N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);

[~~(67)~~] (81) Para-methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 4-methylfentanyl);

(82) Para -methoxyfuranyl fentanyl (N -(4-methoxyphenyl)- N -(1-phenethylpiperidin-4-yl)furan-2-carboxamide);

[~~(68)~~] (83) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);

[~~(69)~~] (84) Phenadoxone;

[~~(70)~~] (85) Phenampromide;

[~~(71)~~] (86) Phenomorphan;

[~~(72)~~] (87) Phenoperidine;

[~~(73)~~] (88) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide) (Other name: benzoyl fentanyl);

[~~(74)~~] (89) Piritramide;

[~~(75)~~] (90) Proheptazine;

[~~(76)~~] (91) Properidine;

[~~(77)~~] (92) Propiram;

[~~(78)~~] (93) Racemoramide;

[~~(79)~~] (94) Thenylfentanyl (N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and salts of isomers;

[~~(80)~~] (95) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);

[~~(81)~~] (96) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl);

[~~(82)~~] (97) Tilidine;

[~~(83)~~] (98) Trimeperidine; and

[~~(84)~~] (99) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide."

SECTION 2. Section 329-14, Hawaii Revised Statutes, is amended by amending subsection (d) to read as follows:

"(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Alpha-ethyltryptamine (AET);

(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);

(3) 2,5-dimethoxyamphetamine (2,5-DMA);

(4) 3,4-methylenedioxy amphetamine;

(5) 3,4-methylenedioxymethamphetamine (MDMA);

(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);

(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);

(8) 5-methoxy-3,4-methylenedioxy-amphetamine;

(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);

(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);

(11) 3,4,5-trimethoxy amphetamine;

(12) Bufotenine;

(13) 4-methoxyamphetamine (PMA);

(14) Diethyltryptamine;

(15) Dimethyltryptamine;

(16) 4-methyl-2,5-dimethoxy-amphetamine;

(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

(18) Ibogaine;

(19) Lysergic acid diethylamide;

(20) Marijuana;

(21) Parahexyl;

(22) Mescaline;

(23) Peyote;

(24) N-ethyl-3-piperidyl benzilate;

(25) N-methyl-3-piperidyl benzilate;

(26) Psilocybin;

(27) Psilocyn;

(28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);

(29) Ethylamine analog of phencyclidine (PCE);

(30) Pyrrolidine analog of phencyclidine (PCPy, PHP);

(31) Thiophene analog of phencyclidine (TPCP; TCP);

(32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;

(33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4-butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4-tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;

(34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;

(35) N-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers;

(36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;

(37) Alpha-methyltryptamine (AMT);

(38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

(39) Salvia divinorum;

(40) Salvinorin A;

(41) Divinorin A;

(42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);

(43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

(44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

(45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

(46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

(47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

(48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

(49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

(50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

(51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

(52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and

geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);

(53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);

(54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);

(55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one);

(56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);

(57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);

(58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);

(59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);

(60) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-chloro-[alpha]-PVP; 4'-chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); [~~and~~]

(61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE)[~~.~~];

(62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one)(other name: bk-EBDB); and

(63) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation."

SECTION 3. Section 329-14, Hawaii Revised Statutes, is amended by amending subsection (f) to read as follows:

"(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Amineptine

[~~(1)~~] (2) Aminorex;

[~~(2)~~] (3) Cathinone;

[~~(3)~~] (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR);

[~~(4)~~] (5) Fenethylline;

(6) Mesocarb (chemical name: *N* -phenyl- *N'* -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);

[~~(5)~~] (7) Methcathinone;

(8) Methiopropamine (*N* -methyl-1-(thiophen-2-yl)propan-2-amine);

[~~(6)~~] (9) 4-methylaminorex;

[~~(7)~~] (10) N-ethylamphetamine;

[~~(8)~~] (11) N,N-dimethylamphetamine;

[~~(9)~~] (12) Substituted cathinones, any compound, except bupropion or compounds listed under a different schedule, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:

(A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(B) By substitution at the 3-position with an acyclic alkyl substituent; or

(C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-

5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and

[~~(10)~~] (13) 1-(4-methoxyphenyl)-N-methylpropan-2-amine (Other names: para-methoxymethamphetamine; PMMA)."

SECTION 4. Section 329-20, Hawaii Revised Statutes, is amended to read as follows:

"**§329-20 Schedule IV.** (a) The controlled substances listed in this section are included in schedule IV.

(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system:

(1) Alprazolam;

(2) Barbital;

(3) Brexanolone;

(4) Bromazepam;

(5) Butorphanol;

(6) Camazepam;

(7) Carisoprodol;

(8) Chloral betaine;

(9) Chloral hydrate;

(10) Chlordiazepoxide;

(11) Clobazam;

(12) Clonazepam;

(13) Clorazepate;

(14) Clotiazepam;

(15) Cloxazolam;

(16) Daridorexant;

(17) Delorazepam;

(18) Diazepam;

(19) Dichloralphenazone (Midrin);

(20) Estazolam;

(21) Ethchlorvynol;

(22) Ethinamate;

(23) Ethyl loflazepate;

(24) Fludiazepam;

(25) Flunitrazepam;

(26) Flurazepam;

(27) Fospropofol (Lusedra);

(28) Halazepam;

(29) Haloxazolam;

(30) Ketazolam;

(31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide);

(32) Loprazolam;

(33) Lorazepam;

(34) Lormetazepam;

(35) Mebutamate;

(36) Medazepam;

(37) Meprobamate;

(38) Methohexital;

(39) Methylphenobarbital (mephorbarbital);

(40) Midazolam;

(41) Nimetazepam;

(42) Nitrazepam;

(43) Nordiazepam;

(44) Oxazepam;

(45) Oxazolam;

(46) Paraldehyde;

(47) Petrichloral;

(48) Phenobarbital;

(49) Pinazepam;

(50) Prazepam;

(51) Quazepam;

(52) Remimazolam;

(53) Suvorexant;

(54) Temazepam;

(55) Tetrazepam;

(56) Triazolam;

(57) Zaleplon;

(58) Zolpidem; [~~and~~]

(59) Zopiclone (Lunesta)[~~.~~]and

(60) Zuranolone.

[~~(c) Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Fenfluramine.~~]

[~~(d)~~] (c) Stimulants. Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central

nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Cathine ((+)-norpseudoephedrine);

(2) Diethylpropion;

(3) Fencamfamin;

(4) Fenproporex;

(5) Lorcaserin;

(6) Mazindol;

(7) Mefenorex;

(8) Modafinil;

(9) Pemoline (including organometallic complexes and chelates thereof);

(10) Phentermine;

(11) Pipradrol;

(12) Serdexmethylphenidate;

(13) Sibutramine;

(14) Solriamfetol; and

(15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).

[~~(e)~~] (d) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its optical isomers and its salts, isomers, and salts of isomers:

(1) Pentazocine; and

(2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid.

[~~(f)~~] (e) The department of law enforcement may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (b) or any stimulant listed in subsection (d) from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant or stimulant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the degree of danger or probable danger of the substances which have a depressant or stimulant effect on the central nervous system.

[~~(g)~~] (f) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit;

(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane); and

(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)."

SECTION 5. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.

SECTION 6. This Act, upon its approval, shall take effect on July 1, 2024.

2025-0011 New Controlled Substances Legislature 2025 Report

Final Audit Report 2025-01-13

Created:	2025-01-13 (Hawaii-Aleutian Standard Time)
By:	Kathy Moriyama (kathy.k.moriyama@hawaii.gov)
Status:	Signed
Transaction ID:	CBJCHBCAABAAJn8eOew3HSR5S1YmtYZGNUN__qHN0D3S
Number of Documents:	2
Document page count:	28
Number of supporting files:	0
Supporting files page count:	0

"2025-0011 New Controlled Substances Legislature 2025 Repor t" History

Document created by Kathy Moriyama (kathy.k.moriyama@hawaii.gov)
2025-01-13 - 6:52:48 AM HST- IP address: 162.221.247.253

Document emailed to Jordan Lowe (jordan.lowe@hawaii.gov) for signature
2025-01-13 - 6:53:17 AM HST

Email viewed by Jordan Lowe (jordan.lowe@hawaii.gov)
2025-01-13 - 7:23:43 AM HST- IP address: 104.47.64.254

Agreement viewed by Jordan Lowe (jordan.lowe@hawaii.gov)
2025-01-13 - 7:23:46 AM HST- IP address: 162.221.247.253

Document e-signed by Jordan Lowe (jordan.lowe@hawaii.gov)
Signature Date: 2025-01-13 - 7:24:01 AM HST - Time Source: server- IP address: 162.221.247.253

Agreement completed.
2025-01-13 - 7:24:01 AM HST

ETS
STATE OF HAWAI'I